History of other previous cancer that would interfere with the determination of safety or efficacy
No other active malignancy that the investigator determines would interfere with the treatment and safety analysis
Patient receiving concomitant therapy, which in the opinion of the Investigator is considered relevant for the evaluation of the efficacy or safety of the trial drug.
Any condition or illness that, in the opinion of the investigator, would compromise patient safety or interfere with the evaluation of the drug
Any other concomitant serious illness or organ system dysfunction in opinion of Investigator would either compromise subject safety or interfere with test drug safety evaluation
Any condition or illness that, in the opinion of the investigator, would compromise patient safety or interfere with the evaluation of the drug
Any other concomitant serious illness or organ system dysfunction which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety of the study drug
Any medical condition that in the judgement of the principal investigator is likely to interfere with assessment of safety or efficacy of study treatment
Other medical or psychiatric illness or organ dysfunction which, in the opinion of the Investigator, would either compromise the subject's safety or interfere with the evaluation of the safety of the study agent.
Any history of or concomitant condition that, in the opinion of the investigator, would compromise the patients ability to comply with the study or interfere with the evaluation of the efficacy and safety of the test drug
Any history of or concomitant condition that, in the opinion of the investigator, would compromise the patients ability to comply with the study or interfere with the evaluation of the efficacy and safety of the test drug
Other medical or psychiatric illness or organ dysfunction, which in the opinion of the investigator, would either compromise the subject's safety or interfere with the evaluation of the safety of the study agent
Uncontrolled concomitant disease that in the opinion of the investigator would interfere with the patients safety or compliance on trial
History of severe autoimmune disease that in the opinion of the investigator would interfere with patient safety or compliance on trial
Has any serious concomitant illness that in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments.
Any medical condition that in the judgement of the investigator is likely to interfere with assessment of safety or efficacy of study treatment
Have any condition or illness that, in the opinion of the investigator would compromise patient safety or interfere with evaluation of the study drug (including but not limited to human immunodeficiency virus [HIV] and hepatitis C virus [HCV])
Have any condition or illness that, in the opinion of the investigator, might compromise patient safety or interfere with the evaluation of the safety of the drug
Any history of or concomitant condition that, in the opinion of the investigator, would compromise the patients ability to comply with the study or interfere with the evaluation of the efficacy and safety of the test drug
History or evidence on physical examination or screening laboratory tests of any systemic disease or any acute or chronic illness that, in the opinion of the investigator, may interfere with the evaluation of the safety or immunogenicity of the study drug
Any serious medical or psychiatric illness, including drug or alcohol abuse that could, in the investigator's opinion, potentially jeopardize the safety of the participant or interfere with the objectives of the study.
Any illness or condition that in the opinion of the investigator may affect safety of treatment or evaluation of any the studys endpoints
Any medical or psychiatric condition, illness, disorder, or concomitant medication that could compromise participant safety or treatment, as determined by the principal investigator and/or study physician
Other active malignancy (other than malignancies, which the investigator determines are unlikely to interfere with treatment and safety analysis)
Have any condition or illness that, in the opinion of the investigator, might compromise patient safety or interfere with the evaluation of the safety of the drug.
Has any serious concomitant illness that in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments
Any other clinical condition that, in the Investigator's judgement, would potentially compromise study compliance or the ability to evaluate safety/efficacy
Patients who have any other life threatening illness or organ system dysfunction, which in the opinion of the investigator, would either compromise patient safety or interfere with the evaluation of the safety of the study drug
Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patients safety or study endpoints
Any serious active disease or co-morbid condition, which in the opinion of the principal investigator, will interfere with the safety or compliance of the trial
Patients must not have any other concomitant serious illness or organ system dysfunction which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety of the study drug
Evidence of clinically significant disease (e.g., cardiovascular, respiratory, gastrointestinal, renal disease) that in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments.
Have any condition or illness that, in the opinion of the investigator, would compromise patient safety or interfere with the evaluation of the study drug.
Any medical condition that, in the opinion of the Investigator, may pose a safety risk to a subject in this trial, may confound the assessment of safety and efficacy, or may interfere with study participation.
Have evidence of any other serious systemic disease, including active bacterial or fungal infection, or any medical condition that, in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments
Known other active malignancy (other than malignancies which the investigator determines are unlikely to interfere with treatment and safety analysis)
Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patients safety or study endpoints
Any illness or condition that in the opinion of the investigator may affect safety of treatment or evaluation of any the studys endpoints
Have any condition or illness that, in the opinion of the investigator, would compromise participants safety or interfere with evaluation of the drug study.
Evidence of clinically significant disease (e.g., cardiovascular, respiratory, gastrointestinal, renal disease) that in the opinion of the investigator could affect the subject safety or interfere with the study assessments
Other medical or psychiatric illness or organ dysfunction that, in the opinion of the investigator, would either compromise the patients safety or interfere with the evaluation of the safety of bevacizumab
Suffer from any other condition or illness that would compromise safety or interfere with evaluation of the drug
Previous medical history, or evidence, of an intercurrent illness that at the discretion of the principal investigator may compromise the safety of the subject in the study
Suffer from any condition or illness that, in the opinion of the investigator, would compromise patient safety or interfere with the evaluation of the safety of the study drug
Any illness or condition that in the opinion of the Investigator may affect safety of treatment or evaluation of any the studys endpoints
Concomitant therapy, which is considered relevant for the evaluation of the efficacy or safety of the trial drug
Any history of or concomitant condition that, in the opinion of the investigator not to comply with the study or interfere with the evaluation of the efficacy and safety of the test drug
Serious concomitant disease or medical condition affecting compliance with trial requirements or which are considered relevant for the evaluation of the efficacy or safety of the trial drug,
Patients with any other life-threatening illness, significant organ system dysfunction, or clinically significant laboratory abnormality, which, in the opinion of the Investigator, would either compromise the patient's safety or interfere with evaluation of the safety of the study drug.
Patients with any other life-threatening illness, significant organ system dysfunction, or clinically significant laboratory abnormality, which, in the opinion of the Investigator, would either compromise the patient's safety or interfere with evaluation of the safety of the study drug
Psychiatric or cognitive illness or recreational drug/alcohol use that, in the opinion of the principal investigator, would affect patient safety and/or compliance.
Systemic cardiac disease that would, in the opinion of the investigator or medical monitor, interfere with assessment of efficacy or safety of the drug
Evidence of clinically significant disease (e.g., cardiovascular, respiratory, gastrointestinal, renal, or infectious disease) that in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments
Any medical or psychiatric condition, illness, disorder, or concomitant medication that could compromise participant safety or treatment, as determined by the principal investigator or collaborator
Any medical or psychiatric condition, illness, disorder, or concomitant medication that could compromise participant safety or treatment, as determined by the principal investigator
Any medical or psychiatric condition, illness, disorder, or concomitant medication that could compromise participant safety or treatment, as determined by the principal investigator and/or study physician
Have any condition that in the opinion of the investigator would confound the efficacy, safety and tolerability assessments, such as oral thrush.
History or current evidence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, hematological, endocrinological, metabolic, neurological, psychiatric, or other diseases, which, in the opinion of the investigator, may affect the subject's safety or interfere with the trial.
Any other local condition including bacterial superinfection which in the opinion of the investigator would interfere with the efficacy evaluation.
any other concomitant serious illness or organ system dysfunction which in the opinion of the investigator would either compromise subject safety or interfere with the evaluation of the safety of the test drug
Subject has another active medical condition(s) or organ disease(s) that may either compromise subject safety or interfere with the safety and/or outcome evaluation of the study drug
